Pacira Pharmaceuticals Statistics
Pacira Pharmaceuticals (82P) Stock Statistics & Valuation Metrics
Total Valuation
Pacira Pharmaceuticals has a market cap or net worth of EUR 1.30B. The enterprise value is EUR 1.07B.
- Market Cap
- EUR 1.30B
- Enterprise Value
- EUR 1.07B
Share Statistics
Pacira Pharmaceuticals has 40,094,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 40,094,660
- Owned by Insiders
- 3.60%
- Owned by Institutions
- 65.98%
Financial Efficiency
Pacira Pharmaceuticals’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 1.20%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 1.20%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 878.37K
- Profits Per Employee
- 8,505.441
- Employee Count
- 827
- Asset Turnover
- 0.57
- Inventory Turnover
- 0.98
Valuation Ratios
The current PE Ratio of Pacira Pharmaceuticals is 38.29. Pacira Pharmaceuticals’s PEG ratio is 0.36.
- PE Ratio
- 38.29
- PS Ratio
- 1.96
- PB Ratio
- 2.04
- Price to FCF
- 8.60
- Price to Operating Cash Flow
- 8.22
- PEG Ratio
- 0.36
Income Statement
In the last 12 months, Pacira Pharmaceuticals had revenue of 726.41M and earned 7.03M in profits. Earnings per share was 0.16.
- Revenue
- 726.41M
- Gross Profit
- 576.66M
- Operating Income
- 33.30M
- Pretax Income
- 16.87M
- Net Income
- 7.03M
- EBITDA
- 122.50M
- Earnings Per Share (EPS)
- 0.16
Cash Flow
In the last 12 months, operating cash flow was 176.90M and capital expenditures -7.90M, giving a free cash flow of 169.00M billion.
- Operating Cash Flow
- 176.90M
- Free Cash Flow
- 169.00M
- Free Cash Flow per Share
- 4.24
Dividends & Yields
Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 11.63%
- Earnings Yield
- 2.60%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- 72.97%
- 50-Day Moving Average
- 26.30
- 200-Day Moving Average
- 21.71
- Relative Strength Index (RSI)
- 77.71
- Average Volume (3m)
- ―
Important Dates
Pacira Pharmaceuticals upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Pacira Pharmaceuticals as a current ratio of 4.54, with Debt / Equity ratio of 65.56%
- Current Ratio
- 4.54
- Quick Ratio
- 3.28
- Debt to Market Cap
- 0.36
- Net Debt to EBITDA
- 2.41
- Interest Coverage Ratio
- 2.28
Taxes
In the past 12 months, Pacira Pharmaceuticals has paid 9.84M in taxes.
- Income Tax
- 9.84M
- Effective Tax Rate
- 0.58
Enterprise Valuation
Pacira Pharmaceuticals EV to EBITDA ratio is 11.77, with an EV/FCF ratio of 9.15.
- EV to Sales
- 2.08
- EV to EBITDA
- 11.77
- EV to Free Cash Flow
- 9.15
- EV to Operating Cash Flow
- 8.74
Balance Sheet
Pacira Pharmaceuticals has EUR 295.58M in cash and marketable securities with EUR 340.28M in debt, giving a net cash position of -EUR 44.70M billion.
- Cash & Marketable Securities
- EUR 295.58M
- Total Debt
- EUR 340.28M
- Net Cash
- -EUR 44.70M
- Net Cash Per Share
- -EUR 1.11
- Tangible Book Value Per Share
- EUR 10.53
Margins
Gross margin is 78.73%, with operating margin of 4.62%, and net profit margin of 5.08%.
- Gross Margin
- 78.73%
- Operating Margin
- 4.62%
- Pretax Margin
- 4.97%
- Net Profit Margin
- 5.08%
- EBITDA Margin
- 17.67%
- EBIT Margin
- 6.47%
Analyst Forecast
The average price target for Pacira Pharmaceuticals is EUR 31.03, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 31.03
- Price Target Upside
- 3.03% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 9
- Revenue Growth Forecast
- -1.49%
- EPS Growth Forecast
- 87.61%
Scores
- Smart Score
- 7
- AI Score
- ―
